Pherin Pharmaceuticals lead program PH94B nasal spray, a Phase 3 ready product, is being developed for the acute treatment of Social Anxiety Disorder under USFDA guidance.

Pherin Pharmaceuticals

Phone Icon (650) 383-4642

Management


Our Management Team

Pherin Pharmaceuticals, Inc. is presently operating under the leadership of a small management team with significant experience in the life sciences industry. Our management team has access to some experts in the fields of pharmaceutical research and development, drug discovery and regulatory affairs. We also have a diversified scientific advisory board comprising world-renowned scientists.

Toby Rosenblatt

Toby Rosenblatt has served as our Director since 1992. At present, Mr. Rosenblatt is Chairman of the Board of Pherin. Mr. Rosenblatt is president of Founders Investments Ltd., which is involved in private investment activities. He also serves as a director of BlackRock Equity Liquidity Mutual Funds and various Foundations and other nonprofit organizations.

Louis Monti, MD., PhD

Louis Monti has served as our vice-president of research since our founding and executive vice president since 2003. At present, Dr. Monti is president and CEO of Pherin. Before joining Pherin, Dr. Monti held various academic positions at the University of Utah and the University of Uruguay. Dr. Monti holds an M.D. degree from the School of Medicine, University of the Republic, Uruguay, and a Ph.D. degree from the School of Medicine, University of Utah. He has published over 100 scientific articles and holds nine patents.

Kevin P. McCarthy

Kevin P. McCarthy has served as our Director since our founding. He formerly served the Company as Senior Vice President and Chief Financial Officer. At present Mr. McCarthy is secretary and treasurer of Pherin. Before joining Pherin, Mr. McCarthy was vice president, chief financial officer and director of Erox Corporation and a managing director of Berliner Associates.

In Remembrance of Julian N. Stern (1924-2018)

Pherin Pharmaceuticals sadly announces the passing of Julian Stern, who served as a founding Director and was Chairman of the Board. We will miss his guidance and vision. Mr. Stern was also a director of DepoMed, Inc., Fibrogen, Inc. and ROXRO Pharma, Inc. as well as corporate secretary of several other public and private biotechnology companies. He was the incorporator of ALZA Corporation and Cetus Corporation (the world's first biotechnology company), and he served as corporate secretary and a director of those companies from their inception until their merger, respectively, into Johnson & Johnson and Chiron Corporation. Mr. Stern was active in some charitable organizations and served as president of the Ronald & Ann Williams Charitable Foundation, as a trustee of the Peter A. & Vernice H. Gasser Foundation and as an honorary lifetime trustee and past chairman of the American Cancer Society, California Division.